对于轻症 可以缓解 There was however a marked reduction of self-reported anosmia/hyposmia, a reduction of cough and a tendency to lower viral loads and lower IgG titers which warrants assessment in larger trials. https://www.sciencedirect.com/science/article/pii/S2589537020304648
Abstract Background Ivermectin inhibits the replication of SARS-CoV-2 in vitro at concentrations not readily achievable with currently approved doses. There is limited evidence to support its clinical use in COVID-19 patients. We conducted a Pilot, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a single dose of ivermectin reduce the transmission of SARS-CoV-2 when administered early after disease onset.
Methods Consecutive patients with non-severe COVID-19 and no risk factors for complicated disease attending the emergency room of the Clínica Universidad de Navarra between July 31, 2020 and September 11, 2020 were enrolled. All enrollments occurred within 72 h of onset of fever or cough. Patients were randomized 1:1 to receive ivermectin, 400 mcg/kg, single dose (n = 12) or placebo (n = 12). The primary outcome measure was the proportion of patients with detectable SARS-CoV-2 RNA by PCR from nasopharyngeal swab at day 7 post-treatment. The primary outcome was supported by determination of the viral load and infectivity of each sample. The differences between ivermectin and placebo were calculated using Fisher's exact test and presented as a relative risk ratio. This study is registered at ClinicalTrials.gov: NCT04390022.
Findings All patients recruited completed the trial (median age, 26 [IQR 19–36 in the ivermectin and 21–44 in the controls] years; 12 [50%] women; 100% had symptoms at recruitment, 70% reported headache, 62% reported fever, 50% reported general malaise and 25% reported cough). At day 7, there was no difference in the proportion of PCR positive patients (RR 0·92, 95% CI: 0·77–1·09, p = 1·0). The ivermectin group had non-statistically significant lower viral loads at day 4 (p = 0·24 for gene E; p = 0·18 for gene N) and day 7 (p = 0·16 for gene E; p = 0·18 for gene N) post treatment as well as lower IgG titers at day 21 post treatment (p = 0·24). Patients in the ivermectin group recovered earlier from hyposmia/anosmia (76 vs 158 patient-days; p < 0.001).
Interpretation Among patients with non-severe COVID-19 and no risk factors for severe disease receiving a single 400 mcg/kg dose of ivermectin within 72 h of fever or cough onset there was no difference in the proportion of PCR positives. There was however a marked reduction of self-reported anosmia/ hyposmia, a reduction of cough and a tendency to lower viral loads and lower IgG titers which warrants assessment in larger trials.
Objectives In this randomized open-label trial pilot study we assessed the antiviral effects and safety of various doses of ivermectin in patients with mild clinical symptoms of COVID-19.
Methods Patients were randomly assigned to receive standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin 200 mcg/kg; or SOC plus ivermectin 400 mcg/kg. The primary assessed endpoint was the proportion of patients who achieved two consecutive negative SARS- CoV-2 RT PCR tests within 7 days of the start of the dosing period. This study was registered at ClinicalTrials.gov (NCT04431466).
Results A total of 32 patients were enrolled and randomized to treatment. SOC treatment together with ivermectin did not result in any serious adverse events. All patients exhibited a reduction in SARS-CoV-2 viral load within 7 days; however, those who received ivermectin had a more consistent decrease as compared to the SOC alone group, characterized by a shorter time for obtaining two consecutive negative SARS-CoV-2 RT PCR tests.
Conclusions Ivermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load. This antiviral effect appears to depend on the dose used, and if confirmed in future studies, it suggests that ivermectin may be a useful adjuvant to the SOC treatment in patients with mild COVID-19 symptoms.
没有做重症的研究
对于轻症 可以缓解 There was however a marked reduction of self-reported
anosmia/hyposmia, a reduction of cough and a tendency to lower viral loads
and lower IgG titers which warrants assessment in larger trials.
https://www.sciencedirect.com/science/article/pii/S2589537020304648
Abstract
Background
Ivermectin inhibits the replication of SARS-CoV-2 in vitro at concentrations not readily achievable with currently approved doses. There is limited
evidence to support its clinical use in COVID-19 patients. We conducted a
Pilot, randomized, double-blind, placebo-controlled trial to evaluate the
efficacy of a single dose of ivermectin reduce the transmission of SARS-CoV-2 when administered early after disease onset.
Methods
Consecutive patients with non-severe COVID-19 and no risk factors for
complicated disease attending the emergency room of the Clínica Universidad de Navarra between July 31, 2020 and September 11, 2020 were enrolled. All enrollments occurred within 72 h of onset of fever or cough. Patients were
randomized 1:1 to receive ivermectin, 400 mcg/kg, single dose (n = 12) or
placebo (n = 12). The primary outcome measure was the proportion of patients with detectable SARS-CoV-2 RNA by PCR from nasopharyngeal swab at day 7
post-treatment. The primary outcome was supported by determination of the
viral load and infectivity of each sample. The differences between
ivermectin and placebo were calculated using Fisher's exact test and
presented as a relative risk ratio. This study is registered at
ClinicalTrials.gov: NCT04390022.
Findings
All patients recruited completed the trial (median age, 26 [IQR 19–36 in
the ivermectin and 21–44 in the controls] years; 12 [50%] women; 100% had
symptoms at recruitment, 70% reported headache, 62% reported fever, 50%
reported general malaise and 25% reported cough). At day 7, there was no
difference in the proportion of PCR positive patients (RR 0·92, 95% CI: 0·77–1·09, p = 1·0). The ivermectin group had non-statistically significant lower viral loads at day 4 (p = 0·24 for gene E; p = 0·18 for gene N) and day 7 (p = 0·16 for gene E; p = 0·18 for gene N) post treatment as well
as lower IgG titers at day 21 post treatment (p = 0·24). Patients in the
ivermectin group recovered earlier from hyposmia/anosmia (76 vs 158 patient-days; p < 0.001).
Interpretation
Among patients with non-severe COVID-19 and no risk factors for severe
disease receiving a single 400 mcg/kg dose of ivermectin within 72 h of
fever or cough onset there was no difference in the proportion of PCR
positives. There was however a marked reduction of self-reported anosmia/
hyposmia, a reduction of cough and a tendency to lower viral loads and lower IgG titers which warrants assessment in larger trials.
Objectives
In this randomized open-label trial pilot study we assessed the antiviral
effects and safety of various doses of ivermectin in patients with mild
clinical symptoms of COVID-19.
Methods
Patients were randomly assigned to receive standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin
200 mcg/kg; or SOC plus ivermectin 400 mcg/kg. The primary assessed endpoint was the proportion of patients who achieved two consecutive negative SARS-
CoV-2 RT PCR tests within 7 days of the start of the dosing period. This
study was registered at ClinicalTrials.gov (NCT04431466).
Results
A total of 32 patients were enrolled and randomized to treatment. SOC
treatment together with ivermectin did not result in any serious adverse
events. All patients exhibited a reduction in SARS-CoV-2 viral load within 7 days; however, those who received ivermectin had a more consistent decrease as compared to the SOC alone group, characterized by a shorter time for
obtaining two consecutive negative SARS-CoV-2 RT PCR tests.
Conclusions
Ivermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load. This antiviral effect appears to depend on the
dose used, and if confirmed in future studies, it suggests that ivermectin
may be a useful adjuvant to the SOC treatment in patients with mild COVID-19 symptoms.
Maybe one day there will be an 180 turn just like the masks, and Fauci will mandate ivermectin to everyone...
不会，福气这么干，就是在大药厂面前自杀。
要是马药或者氯喹真被证明能够降低virus load，
那这俩就不仅是救命了，还能减少传染性，
福气现在别无选择，因为承认马药有效自己就是死，
连着强制疫苗的JB一起完蛋。
硬挺的话看独裁能否成功，成功的话就真的是美国终南山。
【 在 rdfirdfi (rdfi) 的大作中提到: 】
: Maybe one day there will be an 180 turn just like the masks, and Fauci
will
: mandate ivermectin to everyone...
I hope you are right. I don't want to be forced to take ivermectin myself.
【 在 RaoYing (老赵走好) 的大作中提到: 】
: 不会，福气这么干，就是在大药厂面前自杀。
: 要是马药或者氯喹真被证明能够降低virus load，
: 那这俩就不仅是救命了，还能减少传染性，
: 福气现在别无选择，因为承认马药有效自己就是死，
: 连着强制疫苗的JB一起完蛋。
: 硬挺的话看独裁能否成功，成功的话就真的是美国终南山。
: will
有病得治
【 在 RaoYing (老赵走好) 的大作中提到: 】
: 不会，福气这么干，就是在大药厂面前自杀。
: 要是马药或者氯喹真被证明能够降低virus load，
: 那这俩就不仅是救命了，还能减少传染性，
: 福气现在别无选择，因为承认马药有效自己就是死，
: 连着强制疫苗的JB一起完蛋。
: 硬挺的话看独裁能否成功，成功的话就真的是美国终南山。
: will